Contrast agent developer Molecular Biosystems of San Diego has begun clinical trials in Japan for assessment of left ventricular opacification and myocardial perfusion using FS069, the company’s cardiac ultrasound imaging agent.
The action is significant for MBI because it triggers a $2 million milestone payment to the company from its Japanese marketing partner, Chugai Pharmaceuticals of Tokyo. Receiving regulatory approval to sell FS069 in Japan would make the product available in the world’s second largest ultrasound market, according to MBI.
FS069 is sold in other parts of the world as Optison by Mallinckrodt of St. Louis, MBI’s marketing partner for regions outside Japan.
By AuntMinnie.com staff writersDecember 16, 1999
Copyright © 1999 AuntMinnie.com